Budipine
 | |
| Systematic (IUPAC) name | |
|---|---|
| 1-tert-butyl-4,4-diphenylpiperidine[1] | |
| Identifiers | |
| CAS number | 57982-78-2 |
| ATC code | N04BX03 |
| PubChem | 68778 |
| ChemSpider | 62021 |
| Chemical data | |
| Formula | C21H27N |
| Mol. mass | 293.446 g/mol |
| SMILES | eMolecules & PubChem |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. | ? |
| Legal status | |
| Routes | ? |
Budipine is an antiparkinson agent.
Its mechanism of action is not well characterized.[2] However, it is believed to be a NMDA receptor antagonist, and to promote the synthesis of dopamine.[3]
Because it provides additional benefits relative to existing treatments, it probably does not precisely mimic the mechanism of an existing known treatment.[4]
See also
References
- ^ Martndale: The Complete Drug Reference, 35th Ed.
- ^ Reichmann H (October 2006). "Budipine in Parkinson's tremor". J. Neurol. Sci. 248 (1-2): 53–5. doi:. PMID 16784759. http://linkinghub.elsevier.com/retrieve/pii/S0022-510X(06)00235-8.
- ^ "umm.edu". http://www.umm.edu/patiented/articles/what_other_drugs_used_parkinsons_disease_000051_8.htm.
- ^ Przuntek H, Bittkau S, Bliesath H, et al. (May 2002). "Budipine provides additional benefit in patients with Parkinson disease receiving a stable optimum dopaminergic drug regimen". Arch. Neurol. 59 (5): 803–6. doi:. PMID 12020263. http://archneur.ama-assn.org/cgi/pmidlookup?view=long&pmid=12020263.
| |||||||||||||||||||||||||
 | This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
© This material from Wikipedia is licensed under the GFDL